OCGN — Ocugen, Inc. stock price, charts and financials

Latest market price

1.03

+0.03+3.17%

Overview Short InterestFilings

OCGNQT12Ocugen, Inc.·NASDAQ

Overview Short InterestFilings

1.03+3.17%

News

Up 3.2% — Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances (marketbeat.com).

Medium confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

LKFT+5.01%$28.91 CMPS+8.70%$15.00 MESO+3.19%$14.87 FTRE+1.55%$20.28 GHRS+3.50%$28.72 ZYME+4.73%$27.48 NKTR+1.45%$68.36 AGIO+2.00%$33.61

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.22	Insider Own	8.29%	Shs Outstand	339.11M	Perf Week	-6.69%

Market Cap	338.57M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	-1.80%	Shs Float	315.73M	Perf Month	-27.65%

Enterprise Value	325.57M	PEG	-	EPS next Q	-0.06	Inst Own	-	Short Float	31.14%	Perf Quarter	-15.39%

Income	-64.00M	P/S	67.71	EPS this Y	-18.18%	Inst Trans	-	Short Ratio	15.98	Perf Half Y	-59.25%

Sales	5.00M	P/B	-	EPS next Y	-7.69%	ROA	-65.87%	Short Interest	98.31M	Perf YTD	-26.04%

Book/sh	-0.05	P/C	3.39	EPS next 5Y	-	ROE	1688.22%	52W High	2.82 -63.43%	Perf Year	-16.80%

Cash/sh	0.29	P/FCF	-	EPS past 3/5Y	-	ROIC	-92.68%	52W Low	1.00 2.93%	Perf 3Y	137.71%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	25.99% -	Gross Margin	-	Volatility	6.35% 5.75%	Perf 5Y	-85.96%

Dividend TTM	-	EV/Sales	65.11	EPS Y/Y TTM	-10.00%	Oper. Margin	-1504.43%	ATR (14)	0.08	Perf 10Y	-99.45%

Dividend Ex-Date	-	Quick Ratio	0.80	Sales Y/Y TTM	25.00%	Profit Margin	-1786.27%	RSI (14)	29.18	Recom	2.17

Dividend Gr. 3/5Y	-	Current Ratio	0.80	EPS Q/Q	-40.00%	SMA20	-21.08%	Beta	2.22	Target Price	5.00

Payout	0.00%	Debt/Eq	1.03	Sales Q/Q	0.00%	SMA50	-23.41%	Rel Volume	1.28	Prev Close	1.00

Employees	116	LT Debt/Eq	-2.58	Earnings	Nov 04	SMA200	-33.76%	Avg Volume	7.07M	Price	1.03

IPO Date	Dec 03, 2014	Option/Short	No / Yes	EPS/Sales Surpr.	-31.25% 67.41%	Net Debt/EBITDA	0.17	Volume	9,063,026	Change	3.17%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Mar-01-23	Upgrade	Chardan Capital	Neutral → Buy
Aug-23-22	Initiated	Mizuho	Buy
Aug-15-22	Reiterated	HC Wainwright & Co.	Buy
Jun-18-22	Reiterated	Cantor Fitzgerald	Neutral
May-08-22	Reiterated	Chardan Capital	Neutral	$3.50
Apr-25-22	Reiterated	Roth Capital	Neutral
Jun-11-21	Downgrade	Roth Capital	Buy → Neutral
May-07-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-09-21	Downgrade	Chardan Capital	Buy → Neutral
Feb-04-21	Upgrade	HC Wainwright & Co.	Neutral → Buy

Latest News· Times ET

Sep-15-26

Sep-15-2608:02PM

Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advancesmarketbeat.com

Sep-11-26

Sep-11-2607:29AM

Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Criticalseekingalpha.com

Sep-09-26

Sep-09-2601:06PM

12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga

Sep-02-26

Sep-02-2607:56AM

OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophyzacks.com

Sep-01-26

Sep-01-2603:06AM

Ocugen Announces First Patient Dosed In Global Phase 3 Registrational Trial Of OCU410, Modifier Gene Therapy Candidate For GA Secondary To Dry Age-Related Macular DegenerationBenzinga

03:02AM

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degenerationglobenewswire.com

Aug-25-26

Aug-25-2603:02AM

Ocugen to Participate in Upcoming September Investor and Industry Conferencesglobenewswire.com

Aug-16-26

Aug-16-2609:15PM

Brokerages Set Ocugen, Inc. (NASDAQ:OCGN) Price Target at $9.50defenseworld.net

Aug-15-26

Aug-15-2605:03PM

Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readoutsmarketbeat.com

Aug-07-26

Aug-07-2610:21AM

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Fallszacks.com

Aug-06-26

Aug-06-2610:05PM

Ocugen Q2 Earnings Call Highlightsmarketbeat.com

01:04PM

Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcriptseekingalpha.com

06:51AM

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimateszacks.com

03:02AM

Ocugen Provides Business Update with Second Quarter 2026 Financial Resultsglobenewswire.com

Jul-31-26

Jul-31-2603:02AM

Ocugen to Participate in Upcoming August Investor Conferencesglobenewswire.com

Company

Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	5	4	4	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	2	2	—	—	—	—	—	—
Gross Profit	5	2	2	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	27	28	27	—	—	—	—	—	—
Research and Development	37	40	32	—	—	—	—	—	—
Other Operating Expense	1	-3	-2	—	—	—	—	—	—
Operating Income	-61	-63	-55	—	—	—	—	—	—
Interest Expense	3	5	0	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-1	0	1	—	—	—	—	—	—
Net Income Before Taxes	-64	-68	-54	—	—	—	—	—	—
Income Taxes	0	0	0	—	—	—	—	—	—
Consolidated Net Income	-64	-68	-54	—	—	—	—	—	—
Net Income From Continuing Operations	-64	-68	-54	—	—	—	—	—	—
Net Income	-64	-68	-54	—	—	—	—	—	—
EPS (Recurring)	-0.22	-0.23	-0.20	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.22	-0.23	-0.20	—	—	—	—	—	—
EPS (Diluted)	-0.22	-0.23	-0.20	—	—	—	—	—	—
EBITDA	-58	-60	-52	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	62.62	101.25	54.54	—	—	—	—	—	—
Gross Margin	100.00	50.00	50.00	—	—	—	—	—	—
Operating Margin	-1,220.00	-1,575.00	-1,375.00	—	—	—	—	—	—
Net Margin	-1,280.00	-1,700.00	-1,350.00	—	—	—	—	—	—
Shares Outstanding	304	300	271	—	—	—	—	—	—
Market Capitalization	313	405	218	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Musunuri Shankar	Chief Executive Officer	Sep 09 '26	Sale	1.12	525,991	589,110	1,088,035	Sep 11
Johnson-Greene Treerita Essalima	Chief Financial Officer	Jun 15 '26	Buy	1.23	21,000	25,830	521,000	Jun 17
Zhang Junge	Director	Apr 01 '26	Option Exercise	0.79	194,134	154,303	1,359,316	Apr 02
Fernandes Prabhavathi	Director	Nov 26 '24	Buy	0.91	10,000	9,095	10,000	Dec 02
Castillo Kirsten	Director	Nov 22 '24	Buy	0.91	25,000	22,848	75,000	Nov 26
Zhang Junge	Director	Jun 14 '23	Buy	0.50	200,278	99,999	1,077,182	Jun 16
Musunuri Shankar	Chief Executive Officer	Feb 16 '23	Option Exercise	0.33	100,000	33,000	2,290,073	Feb 17
Musunuri Shankar	Chief Executive Officer	Feb 16 '23	Sale	1.08	100,000	108,000	2,190,073	Feb 17
Musunuri Shankar	Chief Executive Officer	Jan 17 '23	Option Exercise	0.51	100,000	51,000	2,327,950	Jan 19
Musunuri Shankar	Chief Executive Officer	Jan 17 '23	Sale	1.28	100,000	128,000	2,227,950	Jan 19
Musunuri Shankar	Chief Executive Officer	Dec 16 '22	Option Exercise	0.51	95,809	48,863	848,349	Dec 20
Musunuri Shankar	Chief Executive Officer	Dec 16 '22	Sale	1.43	95,809	137,007	752,540	Dec 20
Musunuri Shankar	Chief Executive Officer	Oct 14 '22	Option Exercise	0.51	100,000	51,000	852,540	Oct 14
Musunuri Shankar	Chief Executive Officer	Oct 14 '22	Sale	1.66	100,000	166,000	752,540	Oct 14
Kumar Ramesh	Director	Oct 06 '22	Option Exercise	0.51	4,500	2,295	4,500	Oct 07

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.